Your browser doesn't support javascript.
loading
Oncogenic drivers dictate immune control of acute myeloid leukemia.
Austin, Rebecca J; Straube, Jasmin; Halder, Rohit; Janardhanan, Yashaswini; Bruedigam, Claudia; Witkowski, Matthew; Cooper, Leanne; Porter, Amy; Braun, Matthias; Souza-Fonseca-Guimaraes, Fernando; Minnie, Simone A; Cooper, Emily; Jacquelin, Sebastien; Song, Axia; Bald, Tobias; Nakamura, Kyohei; Hill, Geoffrey R; Aifantis, Iannis; Lane, Steven W; Bywater, Megan J.
Affiliation
  • Austin RJ; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Straube J; The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
  • Halder R; Department of Pathology, NYU Grossman School of Medicine, New York, NY, 10016, USA.
  • Janardhanan Y; Laura & Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, 10016, USA.
  • Bruedigam C; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Witkowski M; The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
  • Cooper L; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Porter A; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Braun M; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Souza-Fonseca-Guimaraes F; The University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
  • Minnie SA; Department of Pathology, NYU Grossman School of Medicine, New York, NY, 10016, USA.
  • Cooper E; Laura & Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, 10016, USA.
  • Jacquelin S; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
  • Song A; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Bald T; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Nakamura K; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Hill GR; Frazer Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
  • Aifantis I; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
  • Lane SW; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Centre, Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Bywater MJ; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia.
Nat Commun ; 14(1): 2155, 2023 04 14.
Article in En | MEDLINE | ID: mdl-37059710
ABSTRACT
Acute myeloid leukemia (AML) is a genetically heterogeneous, aggressive hematological malignancy induced by distinct oncogenic driver mutations. The effect of specific AML oncogenes on immune activation or suppression is unclear. Here, we examine immune responses in genetically distinct models of AML and demonstrate that specific AML oncogenes dictate immunogenicity, the quality of immune response and immune escape through immunoediting. Specifically, expression of NrasG12D alone is sufficient to drive a potent anti-leukemia response through increased MHC Class II expression that can be overcome with increased expression of Myc. These data have important implications for the design and implementation of personalized immunotherapies for patients with AML.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematologic Neoplasms Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Hematologic Neoplasms Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2023 Document type: Article Affiliation country: Australia